Cancer Policy Success rates for RPGs at NCI would plummet from 13.4% to 8.3% if Trump’s FY2026 budget is enacted June 06, 2025Vol.51 No.22By Paul Goldberg
Cancer Policy FDA booth stood empty at 2025 ASCO annual meeting June 06, 2025Vol.51 No.22By Jacquelyn Cobb
Cancer Policy ALT GOV: The HHS “resistance” on social media June 06, 2025Vol.51 No.22By Claire Marie Porter
Trials & Tribulations Surviving cancer is often not a patient’s most challenging battle May 30, 2025Vol.51 No.21By Boris C. Pasche
Cancer Policy A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration” May 30, 2025Vol.51 No.21By Jacquelyn Cobb
Cancer PolicyFree The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo May 23, 2025Vol.51 No.20
PodcastThe Directors The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear” May 16, 2025Vol.51 No.19By Katie Goldberg
Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reducedNCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.” May 16, 2025Vol.51 No.19By Jacquelyn Cobb
